419 related articles for article (PubMed ID: 37852736)
21. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
22. Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma.
Marconcini R; Pezzicoli G; Stucci LS; Sergi MC; Lospalluti L; Porta C; Tucci M
Hum Vaccin Immunother; 2022 May; 18(3):1980315. PubMed ID: 34613889
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Eggermont AM; Maio M; Robert C
Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
[TBL] [Abstract][Full Text] [Related]
25. Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions.
Shui IM; Scherrer E; Frederickson A; Li JW; Mynzhassarova A; Druyts E; Tawbi H
Melanoma Res; 2022 Dec; 32(6):393-404. PubMed ID: 36223314
[TBL] [Abstract][Full Text] [Related]
26. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
27. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
[TBL] [Abstract][Full Text] [Related]
28. Melanoma-the therapeutic considerations in the clinical practice.
Adeleke S; Okoli S; Augustine A; Galante J; Agnihotri A; Uccello M; Ghose A; Moschetta M; Boussios S
Ann Palliat Med; 2023 Nov; 12(6):1355-1372. PubMed ID: 37431221
[TBL] [Abstract][Full Text] [Related]
29. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
30. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
31. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for advanced melanoma: current situation in Japan.
Kato J; Uhara H
Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
Zou P; Tang R; Luo M
Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
[TBL] [Abstract][Full Text] [Related]
34. The evolutionary legacy of immune checkpoint inhibitors.
Kaushik I; Ramachandran S; Zabel C; Gaikwad S; Srivastava SK
Semin Cancer Biol; 2022 Nov; 86(Pt 2):491-498. PubMed ID: 35341912
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of melanoma.
Kee D; McArthur G
Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
[TBL] [Abstract][Full Text] [Related]
36. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
37. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
38. New systemic therapies for cutaneous melanoma: why, who and what.
Pampena R; Michelini S; Lai M; Chester J; Pellacani G; Longo C
Ital J Dermatol Venerol; 2021 Jun; 156(3):344-355. PubMed ID: 33913672
[TBL] [Abstract][Full Text] [Related]
39. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
Kluger H; Barrett JC; Gainor JF; Hamid O; Hurwitz M; LaVallee T; Moss RA; Zappasodi R; Sullivan RJ; Tawbi H; Sharon E
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918224
[TBL] [Abstract][Full Text] [Related]
40. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S; Demidov L; Moiseyenko V; Protsenko S; Semiglazova T; Odintsova S; Zukov R; Lazarev S; Makarova Y; Nechaeva M; Sakaeva D; Andreev A; Tarasova A; Fadeyeva N; Shustova M; Kuryshev I
Eur J Cancer; 2021 May; 149():222-232. PubMed ID: 33872982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]